Loading clinical trials...
Loading clinical trials...
A Randomized Controlled Observer Blind Trial to Compare the Immunogenicity and Acceptability of a MF59-adjuvanted Influenza Vaccine Compared to an Inactivated Influenza Vaccine as a Preferred Influenza Vaccine Priming Strategy for Naive Infants 6 to <24 Months of Age
Conditions
Interventions
aTIV Primer
QIV Primer
+2 more
Locations
4
Canada
Vaccine Evaluation Center, BC Children's Hospital
Vancouver, British Columbia, Canada
IWK Health Centre
Halifax, Nova Scotia, Canada
Research Institute of the McGill University health Centre
Montreal, Quebec, Canada
Équipe de recherche en vaccination CHU de Québec-Université Laval
Québec, Quebec, Canada
Start Date
November 1, 2018
Primary Completion Date
July 21, 2021
Completion Date
July 21, 2021
Last Updated
March 28, 2023
NCT07291635
NCT06094010
NCT06417762
NCT06160128
NCT07396428
NCT07310472
Lead Sponsor
Canadian Immunization Research Network
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions